Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Frontiers in Medicine|October 4, 2024
Comparison of ustekinumab, infliximab and combination therapy in moderately to severely active ulcerative colitis - a study protocol of a randomized, multicenter, head-to-head COMBO-UC trialRenata Talar-Wojnarowska, Adam Fabisiak, Hubert Zatorski, et al.
Pharmacological Reports : PR|August 24, 2014
Current overview of extrinsic and intrinsic factors in etiology and progression of inflammatory bowel diseasesMarta Sobczak, Adam Fabisiak, Natalia Murawska, et al.
Chemical Biology & Drug Design|October 4, 2016
Synthesis and evaluation of anti-inflammatory properties of silver nanoparticle suspensions in experimental colitis in miceKrzysztof Siczek, Hubert Zatorski, Anna Chmielowiec-Korzeniowska, et al.
European Journal of Pharmacology|August 25, 2020
Cyclic derivative of morphiceptin Dmt-cyclo-(D-Lys-Phe-D-Pro-Asp)-NH2(P-317), a mixed agonist of MOP and KOP opioid receptors, exerts anti-inflammatory and anti-tumor activity in colitis and colitis-associated colorectal cancer in miceMarta Zielińska, Agata Szymaszkiewicz, Damian Jacenik, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|March 7, 2026
Advanced Combination Therapy in Inflammatory Bowel Disease: What Does the Future Hold?Piotr Eder, Adam Fabisiak, Hubert Zatorski, et al.
Journal of Gastroenterology and Hepatology|August 16, 2021
Scoring system assessing mucosal visibility of upper gastrointestinal tract: The POLPREP scaleMarcin Romańczyk, Bartosz Ostrowski, Katarzyna Kozłowska-Petriczko, et al.
Advances in Clinical and Experimental Medicine : Official Organ Wroclaw Medical University|May 11, 2023
Real-world effectiveness and safety of vedolizumab induction therapy for ulcerative colitis: A prospective nationwide Polish observational studyEdyta Zagórowicz, Halina Cichoż-Lach, Maria Kopertowska-Majchrzak, et al.
Therapeutic Advances in Gastroenterology|February 23, 2023
Real-world outcomes of 54-week vedolizumab therapy and response durability after treatment discontinuation in ulcerative colitis: results from a multicenter prospective POLONEZ studyPiotr Eder, Maria Kłopocka, Halina Cichoż-Lach, et al.
Therapeutic Advances in Gastroenterology|September 6, 2021
Characteristics of patients with moderate-to-severe ulcerative colitis treated with vedolizumab: results from a Polish multicenter, prospective, observational real-life study (the POLONEZ study)Halina Cichoż-Lach, Agata Michalak, Maria Kopertowska-Majchrzak, et al.
BMJ Open|January 5, 2022
Recurrent acute pancreatitis prevention by the elimination of alcohol and cigarette smoking (REAPPEAR): protocol of a randomised controlled trial and a cohort studyKlementina Ocskay, Márk Félix Juhász, Nelli Farkas, et al.
Pageof 4